Status:
RECRUITING
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with mo...
Eligibility Criteria
Inclusion
- Adult patient (≥18 years old)
- Operated on at the HUS between January 1, 2010 and December 31, 2022
- Having undergone primary or interval cytoreductive surgery
- Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin
Exclusion
- Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
- Autres types histologiques de cancer de l'ovaire
- Stades de la maladie FIGO I, II, IIIA et IIIC
- Chirurgie de clôture.
Key Trial Info
Start Date :
April 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 22 2025
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06907771
Start Date
April 22 2024
End Date
December 22 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France
Strasbourg, France